Hypertension as an Adverse Event Potentially Impacting the Therapeutic Efficacy of Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma

Patients with hypertension occurring as an AE within 9 weeks are expected to have better PFS and OS with atezolizumab plus bevacizumab therapy for uHCC.

Authors

Institutions

Publication Details

Journal
Journal of Gastroenterology and Hepatology
Published
2025-09-09
DOI
https://doi.org/10.1111/jgh.70068
Citations
2
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
2.64
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Hypertension as an Adverse Event Potentially Impacting the Therapeutic Efficacy of Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma

Takatoshi Nawa, Kazuki Maesaka, Ryotaro Sakamori, Takeo Usui et al.
2 citations
Journal of Gastroenterology and Hepatology
Hepatocellular Carcinoma Treatment and Prognosis
2.64
article

Hypertension as an Adverse Event Potentially Impacting the Therapeutic Efficacy of Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma

Takatoshi Nawa, Kazuki Maesaka, Ryotaro Sakamori, Takeo Usui, Takahiro Kodama, Yuichi Yoshida, Kengo Matsumoto, Yoshinobu Saito, Sadaharu Iio, Takayuki Yakushijin, Tetsuo Takehara, Mitsuru Sakakibara, Kazuhiro Murai, Yuki Tahata, Hisashi Ishida, Atsushi Hosui, Kazuyoshi Ohkawa, Naruyasu Kakita, Yoshinori Doi, Hayato Hikita, Machiko Kai, Masanori Miyazaki, Tomohide Tatsumi, Akira Doi, Yasutoshi Nozaki, Masanori Nakahara, Kazuho Imanaka, Kumiko Shirai, Ryoko Yamada, N Tatsumi
article en
2 citations

Abstract

Patients with hypertension occurring as an AE within 9 weeks are expected to have better PFS and OS with atezolizumab plus bevacizumab therapy for uHCC.

Journal of Gastroenterology and HepatologyVol. 40(10)
Ashiya University (JP), Osaka University of Economics (JP), Osaka Prefectural Medical Center (JP), Osaka City University (JP), Toyonaka Municipal Hospital (JP), Osaka National Hospital (JP), Osaka City General Hospital (JP), Osaka International Cancer Institute (JP), Ikeda Municipal Hospital (JP), Higashiosaka College & Higashiosaka Junior College (JP), Osaka Rosai Hospital (JP), Kansai Rosai Hospital (JP), Higashi Osaka City General Hospital (JP), Yao Tokushukai General Hospital (JP), Suita Municipal Hospital (JP), Osaka Hospital (JP), Itami City Hospital (JP), Japan Community Healthcare Organization (JP), Takarazuka City Hospital (JP), Hyogo Prefectural Nishinomiya Hospital (JP), Osaka University Hospital (JP), Otemae Hospital (JP), Minoh City Hospital (JP), Osaka International University (JP), The University of Osaka (JP)
Openalex Percentile: Top 9%
Hepatocellular Carcinoma Treatment and Prognosis
2.64
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.